THE APEX TIMES
Shares of Moderna have climbed sharply through 2026, driven largely by progress in a joint melanoma vaccine program and a reported rise in quarterly revenue tied to COVID-related deals outside the United States.
Moderna’s stock has surged about 750% in 2026, according to a market report that points to the company’s melanoma vaccine efforts as the biggest driver of investor optimism. The story frames Moderna’s rise as a bet that its mRNA platform can keep producing clinically meaningful results beyond COVID-19.
The report highlights Moderna’s collaboration with Merck on a melanoma vaccine program, saying Merck’s Phase 3 effort succeeded. Phase 3 trials are the late-stage clinical studies that, if successful, can support regulatory submissions and potential commercialization. While the market piece does not provide details on endpoints, timing, or safety findings, the implication is that the Phase 3 outcome strengthened expectations for future product revenues and leverage for the partnership.
Beyond oncology, the report says Moderna’s third-quarter revenue increased 29%, attributing much of the growth to COVID-related deals abroad. Moderna has previously sold and supplied mRNA vaccine doses and related services in multiple countries as demand for COVID vaccines shifted over time, including through contracts with governments and public health institutions. In this update, the emphasis is on international commercial activity rather than a domestic rebound.
The market article also contrasts Moderna’s situation with the competitive landscape, stating that Pfizer’s rival product sold less. It does not quantify the difference or identify the specific product being referenced, but it suggests that Moderna is capturing more share or experiencing better demand conditions than at least one peer during the period.
Taken together, the report depicts a transition that investors have been watching: Moderna moving from a primarily COVID-centric revenue base toward a pipeline where late-stage oncology results can change the company’s longer-term valuation. That shift matters in biotech because the market often prices the durability of revenue streams and the probability of future approvals, not just near-term sales.
The broader mRNA and vaccine sector context is that multiple companies have competed on manufacturing scale, clinical differentiation, and the ability to land government and health-system contracts. Oncology has become a key area of focus for mRNA platforms because success in treatment development can be more transformative than incremental vaccine performance.
Still, several important specifics remain unclear from the published market post itself. It does not provide the exact third-quarter revenue figure, break out which countries or contract types drove the overseas COVID gains, or state how the melanoma Phase 3 outcome translates into timelines for submissions, manufacturing scale-up, or expected financial contribution.
For readers and market participants, the immediate watch items are whether Moderna and Merck provide additional detail about the melanoma Phase 3 result, including study endpoints and regulatory next steps, and how management characterizes the sustainability of non-U.S. COVID-related revenues as demand patterns continue to evolve. The pace of disclosures and any subsequent guidance updates will likely determine whether the stock’s strong 2026 run is reinforced or gradually tempered by execution realities.
A strong quarter from CoreWeave, a major cloud provider for AI compute, helped quiet worries that technology infrastructure spending could cool. Shares tied to AI chips and networking moved higher alongside the sentiment shift.
The ride-hailing and delivery platform is expanding an expanded McDonald’s partnership across 14 markets, positioning delivery growth as a lever for broader Uber Direct adoption and customer engagement.
A major downgrade cut Nvidia’s target price by about 60 percent, while other Wall Street analysts held bullish outlooks and pointed to higher upside targets.
A Bank of America analyst adjusted Eli Lilly’s price target, saying attention should broaden beyond the company’s weight-loss blockbuster franchise as it prepares for its December Innovation Day.
A new report says Tesla and SpaceX have each formed special committees to review a potential all-stock merger, a move that comes as Tesla prepares to unveil its next-generation Roadster.
A new report says Visa is integrating with Monad to expand the flexibility of its stablecoin settlement network, pointing to surging settlement activity and growing institutional interest in faster, programmable payment flows.
Bank of America sees upside in Qualcomm’s efforts to position the chipmaker as a broader supplier to AI data centers, while still expressing caution on what near-term execution can deliver.
A Wall Street note captured a split view of Advanced Micro Devices, with higher profit expectations offset by a lower price target amid recent market pressure.
A Yahoo Finance report says Cathie Wood’s ARK Investment Management reduced its Amazon position while adding to a basket of aerospace-related names after strong trading activity around a rocket launch company.
A recent pullback has renewed debate over whether Exxon Mobil’s valuation properly reflects its current deal slate, including new activity tied to Venezuela, despite the company’s strong multi-year run.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...